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Background: The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back
pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of
patients. Our lab has reported that this treatment reduces CBP intensity and associated brain activations when
tested in an open labelled preliminary study. Notably, effectiveness of the 5% Lidocaine patch has not been tested
against placebo for treating CBP. In this study, effectiveness of the 5% Lidocaine patch was compared with placebo
in 30 CBP patients in a randomised double-blind study where 15 patients received 5% Lidocaine patches and the
remaining patients received placebo patches. Functional MRI was used to identify brain activity for fluctuations of
spontaneous pain, at baseline and at two time points after start of treatment (6 hours and 2 weeks).
Results: There was no significant difference between the treatment groups in either pain intensity, sensory and
affective qualities of pain or in pain related brain activation at any time point. However, 50% patients in both the
Lidocaine and placebo arms reported a greater than 50% decrease in pain suggesting a marked placebo effect.
When tested against an untreated CBP group at similar time points, the patch treated subjects showed significantly
greater decrease in pain compared to the untreated group (n = 15).
Conclusions: These findings suggest that although the 5% Lidocaine is not better than placebo in its effectiveness
for treating pain, the patch itself induces a potent placebo effect in a significant proportion of CBP patients.
Keywords: Chronic pain, fmri, Clinical trial, Placebo, Lidocaine, Topical analgesicBackground
Multiple lines of evidence suggest that aberrant activity in
sodium channels contributes to chronic pain conditions
that involve neuropathy. Blocking sodium channels such
as with systemic Lidocaine reduces evoked intensity of
acute pain [1-5] and also relieves pain in some patient
populations such as in chronic post herpetic neuralgia
[2,6,7]. The main mechanism through which Lidocaine is
said to act is by inhibition of ectopic discharge in sensi-
tized and hyperactive cutaneous nociceptors. In addition, a* Correspondence: a-apkarian@northwestern.edu
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reproduction in any medium, provided the origcentral analgesic effect of Lidocaine has also been sug-
gested [5,8].
The most advocated mode of Lidocaine administration
is with 5% Lidocaine adhesive patches that are applied to
the affected area and act by local absorption [9,10]. The
systemic absorption is minimal; hence the chances of ad-
verse side effects are low. However, the effectiveness of
patches medicated with Lidocaine (5%) in reducing pain is
less clearly understood. Some recent studies reported that
5% Lidocaine patches either have variable effects or no
effects in acute pain models of pain in healthy subjects
suggesting a partial and inconsistent block of nociceptors
[11-13]. These findings raised important questions regard-
ing the mechanisms and potential efficacy of LidocaineLtd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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Lidocaine patches may be more effective in reducing
pathological pain related with an abnormally increased ex-
pression of sodium channels [14]. This assumption is
based on the fact that chronic pain patients with neuro-
pathic pain conditions such as low back pain, painful dia-
betic neuropathy and complex regional pain syndrome
benefit from treatment with topical Lidocaine, but even
in these conditions, the effects of Lidocaine on pain are
variable between subjects and can range from 29% to
80% of the studied cases [2,11,14-18]. Whether Lidocaine
patches are effective in treating chronic back pain is par-
ticularly unclear since the purported effectiveness of the
treatment is derived from open labelled clinical trials
[18-21]. fMRI studies have also shown central analgesic
effects of 5% Lidocaine, but again these studies were not
controlled for a placebo effect [18,20,22-25].
It is not known whether the 5% Lidocaine patch has a
true pharmacological effect on chronic back pain or if it
is a potent placebo. Here we aimed to study how the 5%
Lidocaine patch compares with a placebo patch in redu-
cing pain of CBP and to investigate brain activity that
can differentiate between the treatments. We hypothe-
sised that pain and related brain activity will diminish
more in participants in the active treatment arm. In a
randomised double-blind, placebo controlled clinical
trial, 30 CBP patients received drug or placebo treatment
and underwent brain imaging to identify activity for fluc-
tuations of spontaneous pain, at baseline and at two time
points (6 hours and 2 weeks) after start of treatment.
Moreover, we investigated inter-individual differences in
pain responses to test whether a subset of patients is
more responsive to Lidocaine treatment than placebo
treatment.
Results
Effects of Lidocaine vs. placebo on CBP pain
The chronic back pain intensity (peak pain in spontan-
eous pain ratings on numerical 0-100 scale and visual
analog 0-10 scale values) and back pain properties (sen-
sory, 0-33 scale, and affective, 0-12 scale, pain qualities
from MPQ) were compared between the two treatment
groups at baseline, 6 hours, and 2 weeks post treatment
using a repeated-measures two-way (drug and placebo
treatment arms by sessions) repeated-measures analysis
of variance (2-RM-ANOVA). The peak rating of spon-
taneous pain and the VAS scores were strongly corre-
lated with each other (R = 0.53, p< 0.002, n = 30), and
since the spontaneous pain was collected during fMRI
acquisition, we designated its peak pain rating as the
pain intensity criterion for brain activity. Also note that
at baseline, there was no significant difference (p> 0.05)
between the two groups in depression scores (BDI), anx-
iety scores (BAI) or neuropathic pain scores (NPS).There was a significant decrease in back pain magni-
tude with treatment duration (F 2,89 = 7.8, p< 0.001) but
no treatment type effect (F1,89 = 0.72, p = 0.4), and no
significant interaction between type and duration of
treatment (F 2,89 = 0.03, p = 0.99). At baseline, the lidocaine
treated group did not show a significant difference in back
pain magnitude from the placebo group (Figure 1A).
Similarly, there was no treatment type effects at the 6
hour (F 1,29 = 0.18, p = 0.89) and 2 week period
(F 1,29 = 1.06, p = 0.31).
For both Lidocaine and placebo treated groups, there
was a decrease in the sensory and affective MPQ scores
for treatment duration (Sensory: F2,84 =11.6, p< 0.0001;
affective F2,84 = 22.66, p = 0.0001), but there was no
treatment type effect at 6 hours (sensory p> 0.5;
affective p> 0.3) or at 2 weeks (sensory p> 0.1;
affective p> 0.4) (Figure 1B-E). Overall, the effects of
Lidocaine patch on CBP pain could not be distin-
guished from that of placebo. Yet, we observe decreased
pain of CBP with continued treatment for both treat-
ment groups. Note that there were no harmful or unin-
tended effects reported by subjects in either group.Effects of Lidocaine vs. placebo on CBP pain related brain
activity
Average group activity map was generated for 30 CBP
patients to determine brain regions reflecting spontan-
eous back pain. The spontaneous pain ratings corre-
lated significantly with BOLD response in the medial
prefrontal cortex, extending from the medial frontal
pole to the genual anterior cingulate cortex (Figure 2A,
Table 1). To correct for task related brain activity con-
founds we subtracted the visual rating activity maps
from the pain rating activity maps (whole-brain paired
t-test). The resultant map showed essentially the same
pattern as the uncorrected map (Figure 2B) (opposite
contrast was null). Furthermore, contrasting between
the Lidocaine and the placebo treated groups (un-
paired t-tests, n = 15 subjects per group) at baseline, at
6 hours, and at 2 weeks of treatment showed no sig-
nificant brain activity. The mean activation maps for
Lidocaine treated and placebo treated groups (n = 15
subjects per group) at baseline again showed spontan-
eous pain related statistically significant activation in
the medial prefrontal and the genual anterior cingulate
cortices (Figure 2C & 2D). However, there was no sig-
nificant mean activation at 6 hrs or at 2 weeks of
treatment in either the Lidocaine treated group, or the
placebo treated group. Overall, we observe a consistent
brain activity at baseline for spontaneous pain of CBP.
However, as back pain magnitude decreases with treat-
ment the related brain activity also decreases in both
groups.
Figure 1 Pain did not differ between chronic back pain (CBP) patients treated with 5% lidocaine patches or with patches containing no
active drug (placebo). A. Variation of CBP pain with treatment type and treatment duration. Treatment duration, but not type, significantly
decreased CBP pain. B-E. Effect of treatment type and duration on sensory (range 0-33) and affective scores (range 0-12) obtained on the McGill
pain Questionnaire (MPQ). Sensory and affective scores decreased with treatment duration for both types of treatment. Error bars represent SEMs.
* p< 0.05, ** p< 0.01 differences from baseline.
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As a next step, we tested the hypothesis that a subset of
susceptible CBP patients benefits more from Lidocaine
treatment than the placebo treatment. For this analysis,
first all subjects were separated objectively into twogroups based on a median split. The median of the abso-
lute change in pain in all subjects was 29.4. Thus, all
subjects that showed more than median change in pain
were designated to the CBP decreasing and those less
than median pain change were assigned to the CBP
Figure 2 Different groupings for brain activity for spontaneous
fluctuations of pain of CBP calculated for brain scans collected
at baseline. Coordinates x = 8, y = 56, z = 20 for A-D (top row are
sagittal, middle horizontal, and bottom coronal slices; middle and
bottom rows: left side is left hemisphere). A. Whole-group average
brain activity for rating spontaneous pain of CBP patients (n = 30
subjects). Brain activity was limited to medial prefrontal cortex (BA 9)
and the genual anterior cingulate cortex (BA 32). B. Contrast
between activity for rating spontaneous pain of CBP and rating
length of a bar varying in time (control for visual, motor, and task
demands; paired t-statistic n = 30 subjects) identifies the same brain
activity as in A. C and D. Brain activity was similar between placebo
(C) and lidocaine (D) treated groups for spontaneous pain of CBP at
baseline (n = 15 subjects per group), and closely matched whole-
group activity shown in activity and contrast maps were generated
using random-effects statistics with z score> 2.3 and cluster
threshold p< 0.01, corrected for multiple comparisons.
Figure 3 Pain for treated and observed groups, and pain when
treated group was subdivided based on pain of CBP decreasing
(CBPd) or persisting (CBPp) after 2 weeks. A. Pain at baseline and
after 2-weeks (visual analog score, VAS, 0-10 score) in CBP patients
who received no interventions or treatment instructions, CBP observed
(n = 15), in contrast to the patients who participated in the clinical
trial for an ineffective treatment, CBP treatment (n = 30). The two
groups started at a similar intensity of back pain but only the CBP
treatment group showed decrease in back pain after two weeks. Error
bars represent SEMs. * p< 0.05. B. Back pain intensity, in CBPd and
CBPp groups, as a function of treatment duration. A median split
shows that on average the group that showed absolute pain change
more than the median had significantly lower pain at the 2 week
time point.
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cent change in pain differed between Lidocaine and pla-
cebo treated subjects within a subset of patients. There
were eight placebo and 7 Lidocaine treated CBP subjects
that had reported a more than median (median = 29.4)
decrease in pain after 2 weeks of treatment and the mean
percent change = 61.4%, SEM=2.04. In the remaining
subjects (below the median value) there were 7 placebo
and 8 Lidocaine treated subjects and the mean percent
change in this group was 3.9%, SEM=0.13 (Figure 3B).
Note that with this grouping, there was no difference in
pain between the groups at the 6 hour time point
(F1,29 = 2.7, p = 0.11).
Next, we compared the change in pain between the
Lidocaine and placebo treated groups within the subsetTable 1 Patient clinical characteristics
Age Duration Sex BDI BAI
Mean 51.36 14.2 14 F 6.6 12.3
SD 9.08 12 16 M 4.2 8.8
Scale/Range years years 20 0-63
BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; NPS, neuropathic painof subjects that showed a more than median decrease in
pain i.e. the CBP decreasing group. The mean percent
change in pain in the Lidocaine treated group (54.7%,
SEM=9.81) was not significantly different (t = 0.25,
p = 0.8) from the placebo treated group (59.7% SEM=
10.316). Moreover, pain related brain activity was not
significantly different between the placebo and Lidocaine
treated subjects within the CBPd subset with a less strin-
gent fixed-effects contrast. Using the same technique,
contrasting brain activity between the Lidocaine and pla-
cebo treated subjects within the CBPp group showed no
significant difference between the two groups.
Is the patch a potent placebo?
The effects of 5% Lidocaine patch were indistinguishable
from the placebo patch, but one remaining question was
the marked reduction in pain observed in both Lidocaine
and placebo treated groups. A greater than 50% reduction
in clinical pain in a large proportion of subjects represents
a marked effect and this analgesia could have been caused
by a number of factors associated with the experiment. ForNPS Sensory MPQ Affective MPQ MQS Pain
55.0 16.5 5.5 4.8 71.6
15.5 7 3.6 6.1 24.1
0-100 0-33 0-12 0-21 0-100
scale; MPQ, McGill Pain Questionnaire; MQS, Medication Quantification Scale.
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from a treatment and the twice daily application of the
patch for two weeks may have acted as a potent placebo.
Alternatively, the reduction in pain in the CBPd group
may have been due to other disease related factors such as
due to natural fluctuations in pain intensity. Therefore, we
compared back pain between the observational group
(CBP observed, n =15) and the treatment group (CBP treat-
ment, n = 30), at baseline and after two weeks. Within this
time period, VAS rating for back pain significantly
decreased for the CBP treatment but not for the CBP observed
group (2-RM-ANOVA for the two groups and visits F
2,43 = 8.33, p = 0.03; post-hoc comparisons show 1. no dif-
ference between groups at baseline, p> 0.1, 2. no differ-
ence between baseline and 2-weeks for CBP observed
group p> 0.6, 3. a significant decrease in VAS pain for
CBP treatment group between baseline, 6.6 ± 0.07, and 2-
weeks, 3.8± 0.09, t58 = 4.3, p< 0.001) (Figure 3A). Note
that between the two groups there was no difference in 1)
back pain duration (CBP treatment 14.2± 0.39 years, in con-
trast to CBP observed 14.5± 0.5, t-test p> 0.9), 2) a border-
line difference in age (t-test, p = 0.06), 3) no difference in
gender (Mann Whitney rank sum test, p = 0.4), and 4) no
difference in depression (t-test, p> 0.4), attesting to the
close match between the treatment and observed CBP
groups. Therefore, we conclude that the presence of the
potential analgesic treatment within the clinical trial set-
ting was critical for the decrease in back pain intensity
observed after two weeks in the CBP treatment group.
Discussion
Here we demonstrate that 5% Lidocaine patch reduces
the magnitude of CBP through a mechanism that cannot
be distinguished from the effects of the placebo patch.
However, pain intensity was reduced in a significant pro-
portion of subjects in the 5% Lidocaine and placebo trea-
ted groups. These findings indicate that the therapeutic
effectiveness of 5% Lidocaine observed in other back
pain studies was due to the potent placebo properties of
the patch itself and not due to a pharmacological action
of the drug.
Placebo controlled clinical trials have shown that sys-
temic or topical Lidocaine reduces severity of chronic
post-herpetic neuropathy, neuropathic pain, and for pain
associated with inflammatory bowel disease [4,26,27].
This is the first placebo controlled clinical trial for 5%
Lidocaine in chronic back pain and our findings indicate
that the analgesic effects of 5% Lidocaine patch on CBP
could not be distinguished from the placebo patch. In
addition, there was a generalized decrease in sensory and
affective pain qualities after treatment, but even in these
measurements, the 5% Lidocaine treated group was not
significantly different from the placebo group. In other
clinical conditions such as painful diabetic neuropathyand complex regional pain syndrome, the drug showed
greater benefit than placebo, but the effectiveness was
variable ranging from 29% to 80% of studied cases
[11,16-19].
The mode of action of topical Lidocaine is not clear
and clearly shows inter individual variability in respon-
siveness between patients with neuropathic pain syn-
dromes and also in evoked pain responses in healthy
subject after treatment. In one study, several patients
with complete loss of electric nerve function and marked
subepidermal nerve-fiber plexus denervation in the per-
ipheral limb showed a response to the Lidocaine patch
[21]. An important implication of this study was that
electric nerve function is not an essential for the
mechanisms of 5% Lidocaine therapeutic action. Even in
healthy subjects, 5% Lidocaine was not more effective
than placebo in treating experimental pain and innocu-
ous sensation including heat evoked pain, mechanical
pain and capsaicin induced pain [11-13]. These negative
findings led to the speculation that the 5% Lidocaine is
too low a dose to effectively block healthy nociceptors,
but may block pathological activity associated with upre-
gulated sodium channels that result in neuropathic pain
[11,14]. The Lidocaine patch has been suggested to affect
neuropathic pain by a local non selective stabilization of
sodium channels on cutaneous afferents at or near the
site of application [1,9]. The findings of the present study
corroborated by other studies raise some questions in
this regard and show that Lidocaine was not more effect-
ive than placebo in treating chronic back pain that does
have a significant contribution from neuropathic sources.
The 5% Lidocaine patch is an off label treatment for
chronic back pain. This treatment has been increasingly
advocated due to its purported effectiveness and is
recommended over other treatments due to fewer side
effects [19,28,29]. The confidence in the efficacy of the
5% Lidocaine patch especially for treating CBP is based
mainly on open labelled trials and the role of placebo an-
algesia in mediating the actions of the 5% Lidocaine
patch had not been tested before. Our findings suggest
that the 5% Lidocaine patch acts as potent placebo and
has no detectable pharmacological effect in either pain
report or in brain activity. The fact that a nearly equal
number of subjects in the Lidocaine and placebo arm
reported a marked decrease in pain indicates that the
effects of just the patch itself irrespective of the presence
of drug can produce analgesia through endogenous pain
regulatory mechanisms associated with placebos [30-32].
A putative placebo mechanism in reducing pain is
reflected by the fact that only the patch treated group as
a whole showed a significant reduction in pain intensity
when compared to a group of CBP patients that were
not given any treatment. This observation explains the
positive findings we had reported in a previous report
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was effective in reducing pain intensity on average ac-
companied with related changes in pain related brain ac-
tivation patterns after treatment [20]. However, in the
present and in the preliminary study, we observed a
marked reduction in clinical pain after treatment that
suggests that the patch induces a potent placebo
analgesia.
However, the present study also demonstrates that not
all subjects responded with analgesia to the patch, and
the percent change in pain was negligible in half of the
subjects. Thus, the placebo effect induced by the patches
is subject to a prominent inter-individual variability and
this extent of variability has not been observed in previ-
ous placebo studies [31,33-35]. This could be because
most placebo studies have studied healthy subjects and
placebo responses in clinical populations may be affected
by disease chronicity. Another prominent factor is that
unlike most placebo studies where a group of subjects is
conditioned to believe in the benefits of the treatment
[36,37], here all patch treated subjects were given similar
open ended instructions that the treatment may or may
not reduce their pain. Thus the psychobiological
mechanisms that lead to reduction or no reduction in
pain would be reflective of each individuals own expecta-
tions, belief in the treatment and anxiety about the treat-
ments potential benefits.
One limitation of this study is that the number of sub-
jects is lower than what would be required for a clinical
trial. However, corroborated by other studies, these find-
ings indicate that a large sample size would result in a
similar outcome. A calculation for the required sample
size to achieve a clinically relevant change in pain of 20
% combined with the present findings required 536 sub-
jects to achieve a desired power of 0.85 (large effect size).
Such a large number of chronic back pain subjects would
be extremely difficult if not unachievable to recruit for
an fMRI study. Nevertheless, additional studies are
needed that test the effects of the 5% Lidocaine patch
against a placebo to arrive at a solid conclusion regard-
ing the efficacy of this treatment in chronic back pain.
Recently, the 5% Lidocaine patch has emerged as first
line therapy and since side effects are lower than oral or
systemic doses, its use has become popular especially in
geriatric populations. Our findings raise some important
considerations since even though the 5% Lidocaine had
no direct effect; the patch itself induces analgesia that is
two to three folds higher than the accepted clinical level
of 20% , but a discussion about the ethics of using place-
bos that produce strong analgesic effects is beyond the
scope of the objectives of this study. This study brings to
bear “the elephant in the room” issue relating to the ever
present placebo effect in analgesic trials. This study also
raises the need for more consideration into whether theclinical use of the Lidocaine patch in CBP is warranted.
Overall, based on these findings, we conclude that the
5% Lidocaine patch has no drug mediated action on in-
tensity of CBP; however, it does reduce pain intensity in
more than 50% of subjects that is most likely due to a
placebo effect. Our findings suggest that the patch is a
potent agent for inducing placebo analgesia.
Methods
Subjects
A sample size of 30 subjects was predetermined based on
a a review of literature [4,38]. A total of 38 patients were
recruited for the brain imaging and treatment study. As
shown in the consort flow chart shown in Figure 4, data
from 7 subjects was not analyzed due to failure to attend
the repeat sessions for non specific reasons and data from
1 subject was excluded from analysis due to technical
faults. Thus, data from a total of 30 subjects (16 males,
14 females, age 51.36 ± 0.30 years, mean ± SEM) was
included in the brain imaging analysis. An additional 15
patients (10 males, 5 females, age 46.3 ± 0.38 years) were
recruited and their pain was measured at intervals similar
to the patch treated groups. Brain imaging data was not
collected in this group.
All subjects were right-handed and gave informed con-
sent to procedures approved by the Northwestern Uni-
versity Institutional Review Board. Participants were
compensated financially for their time. All patients,
recruited by newspaper ads in Chicago area, were diag-
nosed with CBP by a clinician and had to fulfill a specific
list of inclusion/exclusion criteria. Patients were included
if they had CBP for >1 year, and a pain score> 4/10 VAS
at the baseline visit. Subjects were excluded if they suf-
fered from co-morbidities, major psychiatric conditions
or other medical conditions (Table 2). Patients who
entered the brain imaging and treatment group were
given specific instructions regarding the potential pain
relief by the patch and were also told that they had a
50% chance of receiving either patches containing drug
or placebo. During the 2 weeks of treatment period, they
could take up to 2 regular strength acetaminophen
tablets (325 mg) per day, if needed. All patients were
asked to refrain from taking analgesic medications for
72 hours prior to the imaging session. Patients who
entered the observational group were not given any
instructions, were not administered any treatments, and
were instructed that they can manage their pain by any
means they deemed necessary.
Subject groups and experimental sessions for brain
imaging with treatment
Efficacy for pain relief by 5% Lidocaine patch was tested in
a randomised, double blind, placebo controlled longitudinal
study. Of the patients recruited to this part of the study,
Figure 4 Consort 2012 flowchart.
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taining 5% Lidocaine and 15 age and sex matched CBP
patients that received a patch containing the vehicle and no
Lidocaine (placebo arm) were included in the analysis. Par-
ticipants were randomly selected to receive drug or pla-
cebo. The Northwestern University Clinical Unit personnel
generated the random allocation sequence using a random
number generator, and held its key to the end of the study.
All patients and experimenters (while delivering treat-
ments, scanning and analyzing data) were blinded to type
of treatment. The first application of the unlabeled patch
was carried out by a clinician (blinded to type of treatment)
who also explained the proper use of the patch. The patient
was supplied with a measured number of unlabeled patches
(identical between drug and placebo arms) and specific
instructions were given to self administer the patch twice
daily at 12 hour intervals for a period of two weeks. There
was no difference in the appearance of the patches that
contained Lidocaine or no drug.Table 2 Coordinates of brain regions activated in relation to
Brain Region Z-VALUE
CBP baseline activitypain task r MPFC/gACC 5.29
(BA 9, 32)
CBP baseline activity r MPFC/gACC 4.61
pain task> visual control (BA 9, 32)
Lidocaine: CBP baseline activity r MPFC/gACC 3.66
pain task (BA 9, 32) 3.25
Placebo: CBP baseline activity r MPFC/gACC 3.95
pain task (BA 9, 32)Experimental tasks and fMRI data acquisition
Each volunteer in this group participated in three experi-
mental sessions. The first session was conducted imme-
diately before start of treatment (baseline), the second
session was performed 6 hours after application of the
first set of patches and the third session was after 2
weeks of using the patches. At baseline, the patients
filled out questionnaires related to their pain that
included the McGill pain questionnaire (MPQ), neuro-
pathic pain scale (NPS), Beck depression inventory (BDI)
and Beck anxiety inventory (BAI). Before scanning, parti-
cipants were trained on a finger-span device that was
later used for acquiring continuous ratings of the fluc-
tuations of spontaneous pain of CBP, on a numerical
scale ranging from 0-100 during functional scans. This
device was composed of a potentiometer the voltage of
which was digitized and time-stamped in reference to
fMRI image acquisition and connected to a computer
providing visual feedback of the ratings [39,40]. Inspontaneous ratings of CBP
co-ordinatesx y z P - values
12 56 22 0.001
12 42 24 0.004
16 36 20 0.004
6 42 18 0.040
12 38 18 0.0003
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perform a visual rating task [39] during which subjects
rated the changes in the length of a bar on the 0-100 nu-
merical rating scale projected on a screen. The length of
the bar varied over time to match the pain ratings
obtained from the subject in the preceding scan. Thus
this task serves as a control for task-related activations
such as visual inputs, motor performance, magnitude es-
timation, attention, and anticipation.
After training, the subjects were placed in the scanner,
T1-weighted structural images and fMRI data were col-
lected while subjects performed pain or visual rating
tasks In addition to the pain rating scan, a visual rating
task scan was acquired in which the subject rated the
length of the bar as it varied over time in conjunction
with the subjects own pain ratings obtained in one of the
preceding spontaneous pain rating scans.
fMRI data were acquired with a 3-T Siemens Trio
whole body scanner with echo-planar imaging (EPI) cap-
ability using the standard radio-frequency head coil.
Multislice T2*-weighted echoplanar images were
obtained with the following parameters: repetition time
(TR) = 2.5 s; echo time (TE) = 30 ms; flip angle = 90°, slice
thickness = 3 mm, in-plane resolution = 64 × 64. The 36
slices covered the whole brain from the cerebellum to
the vertex. A total of 244 volumes were acquired per
condition in all participants and the first 4 volumes were
discarded during the preprocessing step. A T1-weighted
anatomical MRI image was also acquired for each subject
using the following parameters: TR= 2.1 s, TE= 4.38 ms,
flip angle = 8°, field of view = 220 mm, slice thickness = 1
mm, in-plane resolution = 0.86 × 0.86 mm2, and number
of sagittal slices = 160.
Session 2 (6 hrs) and 3 (2 weeks) procedures were
similar to session 1, patients filled out MPQ at all three
time points. Some subjects had missing values in sensory
and affective scores (n = 3 at 6 hour and n = 2 at 2 weeks)
scores in the MPQ and were not included in correspond-
ing statistical testing. This was followed by scanning pro-
cedures identical to those used at baseline.
The CBP patients in the observational group received
no treatment. They filled out the McGill Pain Question-
naire at baseline and after a two-week period. They too
were trained on the finger span device and had fMRI
scan at their second visit (not analyzed for the present
study). For this group, change in back pain was assessed
between baseline and the second visit, using the visual
analog scale (VAS) of the MPQ questionnaire.
Image pre-processing and GLM analysis
Image analysis to reveal significant brain activity based
on changes in blood oxygen level-dependent (BOLD) sig-
nal was performed on each patient’s data using Func-
tional Magnetic Resonance Imaging of the Brain(FMRIB) Expert Analysis Tool [(FEAT; [41]; http://www.
fmrib.ox.ac.uk/fsl)]. The data pre processing were con-
ducted using the FSL 4.1 [41] and MATLAB 7.9. First,
the skull of brain was extracted and the first 4 volumes
were removed to compensate for scanner drifts. More-
over, typical FSL preprocessing was implemented which
includes slice-time correction spatial smoothing with
5mm kernel, intensity normalization, and high-pass fil-
tering (150 sec). The mean BOLD signal from white mat-
ter, cerebrospinal fluid, and whole brain without skull
and the 6 motion components from motion correction,
and motion outlier vectors were regarded as covariates
of no interest and regressed out from the BOLD signal.
In addition, probabilistic Independent Component Ana-
lysis was then implemented in MELODIC (Multivariate
Exploratory Linear Decomposition into Independent
Components) to select artefact components, using an
automated procedure that identified and removed edge
components and signal dropout components. The fMRI
signal was then linearly modeled on a voxel by voxel
basis using FMRIB’s Improved Linear Model (FILM) with
local autocorrelation correction [42,43].
Analysis of effects of Lidocaine vs. placebo
For this step, the experimenter was given a code that
separated the subjects into two groups. However, the ex-
perimenter was not informed about the type of treat-
ment (5% Lidocaine or placebo). The chronic back pain
intensity (peak pain in spontaneous pain ratings on nu-
merical scale and visual analog scale values) and back
pain properties (sensory and affective pain qualities)
were compared between the two groups at all three scan
sessions using a repeated measures analysis of variance.
Brain function in the two groups was assessed for
each session for ratings of spontaneous pain and for vis-
ual control ratings. Ratings were binarized relative to
the mean rating of spontaneous fluctuations of back
pain [39] and convolved with a canonical hemodynamic
response function (gamma function: lag, 6 s; SD, 3 s).
The significance of the model fit to each voxel time
series was calculated, yielding statistical parametric
maps for each subject and condition. All group level
analyses were carried out using FEAT in a random
effects analysis after the co-registration of individual
scans to standard space [152 subject average Montreal
Neurological Institute (MNI) space, http://www.bic.mni.
mcgill.ca/cgi/icbm_view/]. Average group activity map
was generated for 30 subjects to ascertain the region
that corresponds significantly with spontaneous pain
ratings. The next averaged map was generated by sub-
tracting the visual activity maps from the pain activity
maps with a paired t-test. Subsequently, averaged maps
for each group (5% Lidocaine and placebo) were gener-
ated for the three time points. Furthermore, brain
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cebo group at all three time points using a random effects
unpaired t-test analysis. These contrasts result in Z-score
maps of statistically significant pain-related activity across
different conditions. To correct for multiple comparisons,
cluster-based corrections of the Z-statistic images were
performed. The raw Z-statistic images from the group
analysis were thresholded at Z-scores> 2.3. For each
resulting cluster of spatially connected voxels surviving
the Z threshold, a cluster probability threshold of p< 0.05
was applied to the computed significance of that cluster,
which corrects for multiple comparisons according to
Gaussian random field theory [44]. All imaging analyses
were corrected for confounds due to age, sex and depres-
sion (BDI) scores.
Interindividual differences in treatment response
To investigate inter individual differences in treatment
response we selected the 2 week period as the time point
of interest and calculated change in pain from baseline.
The median change was used to regroup CBP into per-
sistent and decreasing (CBPp and CBPd). The question-
naire data was analyzed to assess differences between the
two groups.
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